Curiosity, Research, and Translation: The MIT Roots of Kelonia Therapeutics
Featured in September 2026 newsletter When Michael Birnbaum’s lab began developing a new way to track what T cells recognize, the goal was not to start a company. Long before the company he co-founded, Kelonia Therapeutics, was acquired by Eli Lilly and Company in April 2026, Birnbaum sought to answer a fundamental immunology question about […]